Obesity drugs: approvals meet tighter coverage
- The FDA approved oral semaglutide as the first GLP-1 pill for weight loss, with Novo Nordisk planning a U.S. launch in January 2026. - Lilly’s Foundayo also received FDA approval, even as analyses show about 12 million people lost coverage for Wegovy and Zepbound last year. - Insurers are tightening reimbursement, proposed Medicare pilots face insurer reluctance, and Amazon’s entry into distribution is reshaping access and supply. ( )
The Food and Drug Administration is approving new obesity pills faster than insurers are agreeing to pay for them. (fda.gov; npr.org) Novo Nordisk’s oral semaglutide, sold as a Wegovy pill, became the first glucagon-like peptide-1 pill cleared for weight loss on Dec. 22, 2025, and the company said it would launch in the U.S. in January 2026. Eli Lilly’s Foundayo, the brand name for orforglipron, won Food and Drug Administration approval on April 3, 2026, under the agency’s National Priority Voucher pilot. (ajmc.com; fda.gov; pharmexec.com) These drugs work by copying gut hormones that curb appetite and slow stomach emptying, which can help patients eat less over time. The new approvals matter because both products are pills, not weekly injections, and drugmakers are betting that easier dosing will widen the market. (ajmc.com; pharmexec.com) Coverage is moving the other way. GoodRx found that from 2025 to 2026 about 12 million people lost commercial coverage for Wegovy and about 12 million lost coverage for Zepbound, according to reporting by NPR. (npr.org; goodrx.com) Pharmacy benefit managers and insurers have been narrowing formularies, the covered-drug lists that determine what patients can get at the pharmacy counter. CVS Caremark moved to prefer Wegovy on some standard commercial formularies and exclude Zepbound beginning July 1, 2025, a decision Reuters said continued to weigh on Lilly this week. (pharmaphorum.com; newsbreak.com) Medicare access is also shifting. After insurers balked at joining the BALANCE pilot, the Trump administration delayed the Part D portion and said Medicare would instead offer a bridge program for Wegovy and Zepbound from July 1, 2026, through Dec. 31, 2027. (biospace.com; usatoday.com; axios.com) The Food and Drug Administration’s approval of Foundayo did not end scrutiny. Reuters and CNBC reported on April 14 that the agency asked Lilly for added cardiovascular and liver safety data and requested post-marketing studies after reviewing liver-injury reports. (cnbc.com; biospace.com) Amazon is now trying to control more of the route from diagnosis to delivery. Amazon One Medical launched a national program on April 21 that combines obesity visits with Amazon Pharmacy dispensing, with insured patients advertised as paying as little as $25 a month and cash prices for oral drugs starting at $149. (cnbc.com; usatoday.com) Drugmakers say broader supply and new formats should make treatment easier to start and stay on. Insurers and pharmacy benefit managers are still treating obesity drugs as a budget problem first, which means the next fight is less about approval than about who gets a paid claim. (ajmc.com; npr.org; cnbc.com)
